ArticleFrontiers in medicine2026
Smoking and mortality risk in COPD patients: a prospective cohort study in Sichuan, China.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the association between smoking and mortality in patients with chronic obstructive pulmonary disease (COPD) in Sichuan Province, China. Methods: Data concerning COPD patients in Pengzhou, Sichuan was collated from the China Kadoorie Biobank (CKB). COPD was defined as post-bronchodilator forced expiratory volume in 1 s/forced vital capacity of <70%. The relationship between smoking and mortality was evaluated by Cox proportional hazards regression. Results: Eight thousand five hundred one COPD patients, aged 30-79 years, were enrolled enabling analysis of 85,600 person-years of follow-up data (mean follow-up: 10.07 years). Two thousand deaths occurred during the period of investigation, including 665 from COPD and 1,116 from cardiovascular disease (CVD). Ex-smokers were at higher risk of both all-cause mortality [hazard ratio (HR) 1.56; 95% confidence interval (CI) 1.36-1.80], COPD (HR 2.24; 95% CI 1.80-2.80) and CVD mortality (HR 1.54; 95% CI 1.28-1.85) than those who had never smoked. An increased duration of smoking was associated with higher risk of death. A dose-response relationship was observed. Patients who smoked > 20 g tobacco/day had 35% higher all cause, 66% higher COPD and 34% higher CVD mortality risk. Those with cumulative exposures ≥ 250,000 g had the highest risks of all outcomes. Earlier age of smoking onset and oral only smoke intake (as opposed to lung inhalation) were also linked to greater mortality risk. Conclusion: Smoking was an independent risk factor for COPD-specific, CVD and all-cause mortality in COPD patients from Sichuan with higher tobacco consumption giving a stronger association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.